drugset / Trial / NCT00129532

Trial of SAVVY and HIV in Ghana

NCT00129532

RandomizedParallel-groupDouble-blindPrevention

Summary

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

Timeline

Start
2004-01
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject C31G Unknown 1 % Other